Start-up Australia invests in bone-building tech
Monday, 04 April, 2005
Venture capital fund Start-up Australia Ventures has invested AUD$3 million in junior biotech Caldeon, which is collaborating with the University of Western Australia to optimise osteoporosis drug leads which could reduce bone loss.
"This discovery is a genuine first in the bone metabolism field. This is the first agent to be discovered that specifically stimulates and protects the specialised cells responsible for forming bone," said Prof Ming-Hao Zheng, a co-discoverer of the compounds, along with Dr Jiake Xu and Dr Tony Phan.
Start-up Australia has $55 million under management. Its previous investmest include Alchemia, EvoGenix, Mimetica, Promics, Protagonist, Cortical, Iliad Chemicals and Replikun Biotech
The funding is to be supplied in milestone-based tranches.
Common arthritis drug also lowers blood pressure
Scientists have known for a while that methotrexate helps with inflammation, but it may also help...
AI enables precise gene editing
A newly developed tool utilises AI to predict how cells repair their DNA after it is cut by gene...
Shingles vaccine may reduce risk of heart attack and stroke
Vaccination with either the recombinant herpes zoster vaccine or the live-attenuated zoster...
